ALPEGA
12.3.2024 15:58:32 CET | Business Wire | Press release
Alpega, a leading global logistics SaaS software company, proudly announces its remarkable achievements for the fiscal year 2023, significantly surpassing targets for the third consecutive year. Alpega exceeded revenue and EBITDA objectives underpinned by strong bookings and new business opportunities, which is testimony to the strong traction that the Alpega solutions have with our customers. This success marks a significant milestone as Alpega now surpasses the prestigious 'Rule of 40' territory, a hallmark of excellence for SaaS software companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305956634/en/
(Photo: Alpega)
"In 2023, our remarkable performance underscores Alpega's steadfast commitment to delivering exceptional value to our customers." declared Todd DeLaughter, Alpega CEO. "Our core competency lies in leveraging our extensive carrier-based assets to provide tangible benefits to both shippers and carriers across a diverse range of solutions in Execution, Planning, Sourcing and Payments. As the sole SaaS provider offering Transport Management Systems (TMS) for shippers alongside an 80,000-strong open carrier network, covering approximately 10% of all commercial trucks in Europe, we lead the charge in innovation and efficiency. With these carriers connected through three premier freight exchanges in Europe, boasting strong leadership in Iberia, Romania, and Central and Southeastern European countries, we offer unparalleled connectivity and efficiency, facilitating the seamless matching of available freight loads with transportation capacity."
Alpega's ability to consistently exceed expectations and achieve such remarkable milestones is a testament to its unwavering dedication to excellence and customer satisfaction. As the company continues to push boundaries and redefine industry standards, it remains poised for even greater success in the years ahead.
Alpega
Alpega is a leading global logistics SaaS software company, dedicated to delivering end-to-end solutions that comprehensively address all transport requirements. Our mission is to empower shippers and carriers through efficient digitalization to meet today’s logistics challenges, driving smarter logistics for a greener tomorrow.
Drawing on extensive carrier-based assets, Alpega delivers tangible benefits across Execution, Planning, Sourcing and Payment solutions. As the sole SaaS provider offering Transport Management Systems (TMS) for shippers, coupled with an 80,000-strong open carrier network covering around 10% of all commercial trucks in Europe, we are at the forefront of innovation and efficiency. For our carriers, our connectivity extends through three premier freight exchanges in Europe, with notable leadership in Iberia, Romania, Central, and Southeastern European regions, facilitating seamless matching of freight loads with transportation capacity.
With over three decades of expertise in transportation, we empower businesses to streamline their supply chain planning and execution, resulting in reduced costs and heightened visibility. Alpega's suite of solutions synergistically generates added value for our customers. Our community comprises 80,000 carriers and 200,000 members, seamlessly connected electronically each day to efficiently manage vital transport operations. Operating in 80 countries globally, Alpega boasts a diverse team of over 600 professionals representing 31 nationalities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305956634/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
